Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

PureTech Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

PureTech Health wird ein jährliches Gewinn- und Umsatzwachstum von 2.9% bzw. 53.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich sinken um 47.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -98.4% betragen.

Wichtige Informationen

4.6%

Wachstumsrate der Gewinne

-47.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	60.1%
Zukünftige Eigenkapitalrendite	-98.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	28 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 18

Recent updates

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

Aug 27

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 18

We're Not So Sure You Should Rely on PureTech Health's (LON:PRTC) Statutory Earnings

Jan 18

Is PureTech Health plc (LON:PRTC) Popular Amongst Insiders?

Nov 24

Gewinn- und Umsatzwachstumsprognosen

LSE:PRTC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	47	-253	N/A	N/A	1
12/31/2025	37	-191	-198	-191	2
12/31/2024	N/A	-213	-196	-189	1
12/31/2023	3	-66	-106	-106	N/A
9/30/2023	8	-56	-132	-131	N/A
6/30/2023	12	-47	-157	-157	N/A
3/31/2023	14	-49	-169	-168	N/A
12/31/2022	16	-50	-181	-179	N/A
9/30/2022	17	-32	-183	-179	N/A
6/30/2022	19	-14	-185	-180	N/A
3/31/2022	18	-37	-174	-169	N/A
12/31/2021	17	-61	-164	-158	N/A
9/30/2021	14	-127	-156	-150	N/A
6/30/2021	11	-193	-147	-141	N/A
3/31/2021	11	-94	-142	-136	N/A
12/31/2020	12	6	-137	-132	N/A
9/30/2020	12	239	-121	-115	N/A
6/30/2020	12	472	-104	-99	N/A
3/31/2020	11	446	-107	-99	N/A
12/31/2019	10	421	-111	-98	N/A
9/30/2019	15	229	-103	-91	N/A
6/30/2019	20	37	-96	-84	N/A
3/31/2019	20	-3	-87	-78	N/A
12/31/2018	21	-44	-77	-73	N/A
9/30/2018	14	9	-84	-81	N/A
6/30/2018	7	61	-91	-88	N/A
3/31/2018	5	44	-91	-88	N/A
12/31/2017	3	26	-91	-89	N/A
9/30/2017	4	-17	N/A	-81	N/A
6/30/2017	5	-61	N/A	-74	N/A
3/31/2017	5	-55	N/A	-66	N/A
12/31/2016	4	-49	N/A	-58	N/A
9/30/2016	3	-54	N/A	-57	N/A
6/30/2016	1	-59	N/A	-55	N/A
3/31/2016	6	-49	N/A	-42	N/A
12/31/2015	12	-39	N/A	-29	N/A
9/30/2015	12	-37	N/A	-19	N/A
6/30/2015	12	-35	N/A	-9	N/A
3/31/2015	7	-38	N/A	-10	N/A
12/31/2014	2	-42	N/A	-11	N/A
12/31/2013	9	-5	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PRTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PRTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PRTC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PRTC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: PRTC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PRTC wird voraussichtlich in 3 Jahren unrentabel sein.

PureTech Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 88%

Consensus EPS estimates fall by 29%

Consensus forecasts updated

Consensus forecasts updated

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Analysts update estimates

Recent updates

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

Consensus revenue estimates fall by 88%

First half 2023 earnings: EPS and revenues miss analyst expectations

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 29%

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

Consensus forecasts updated

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Consensus forecasts updated

Is PureTech Health (LON:PRTC) A Risky Investment?

Full year 2021 earnings: EPS and revenues exceed analyst expectations

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

President recently bought UK£51k worth of stock

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought UK£73k worth of stock

Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Is PureTech Health (LON:PRTC) Using Too Much Debt?

Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS

First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020)

President recently bought UK£83k worth of stock

PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202

President recently bought UK£69k worth of stock

PureTech Health plc (LSE:PRTC) acquired the remaining 22% stake in Alivio Therapeutics.

Puretech’s Gelesis Presents Plenity Data at American Association of Clinical Endocrinology 2021

COO, Secretary & Executive Director has left the company

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2020 earnings released

PureTech Health plc Announces Executive Changes

PureTech Health plc to Report Fiscal Year 2020 Final Results on Apr 15, 2021

PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release